JPH0925236A - Alkaline electrolytic water containing zinc - Google Patents
Alkaline electrolytic water containing zincInfo
- Publication number
- JPH0925236A JPH0925236A JP7175968A JP17596895A JPH0925236A JP H0925236 A JPH0925236 A JP H0925236A JP 7175968 A JP7175968 A JP 7175968A JP 17596895 A JP17596895 A JP 17596895A JP H0925236 A JPH0925236 A JP H0925236A
- Authority
- JP
- Japan
- Prior art keywords
- water
- zinc
- electrolytic water
- electrolyzed water
- alkaline electrolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 50
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 13
- 239000011701 zinc Substances 0.000 title claims abstract description 13
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 abstract description 14
- 229960001763 zinc sulfate Drugs 0.000 abstract description 14
- 229910000368 zinc sulfate Inorganic materials 0.000 abstract description 14
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 7
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 7
- 230000002159 abnormal effect Effects 0.000 abstract description 5
- 206010012735 Diarrhoea Diseases 0.000 abstract description 4
- 208000019902 chronic diarrheal disease Diseases 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 239000003651 drinking water Substances 0.000 abstract description 4
- 235000020188 drinking water Nutrition 0.000 abstract description 4
- 201000006549 dyspepsia Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 238000000855 fermentation Methods 0.000 abstract description 4
- 230000004151 fermentation Effects 0.000 abstract description 4
- 206010020601 Hyperchlorhydria Diseases 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 3
- 208000010668 atopic eczema Diseases 0.000 abstract description 3
- 230000003628 erosive effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 231100000397 ulcer Toxicity 0.000 abstract description 3
- 150000003752 zinc compounds Chemical class 0.000 abstract description 3
- 239000011670 zinc gluconate Substances 0.000 abstract description 3
- 229960000306 zinc gluconate Drugs 0.000 abstract description 3
- 235000011478 zinc gluconate Nutrition 0.000 abstract description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract description 2
- 238000007796 conventional method Methods 0.000 abstract description 2
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000010247 contact dermatitis Diseases 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 235000010418 carrageenan Nutrition 0.000 description 8
- 229920001525 carrageenan Polymers 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、亜鉛を含有することを
特徴とするアルカリ性電解水に関する。更に詳しくは亜
鉛並びにアルカリ性電解水を有効成分として含有するこ
とを特徴とする皮膚炎治療剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to alkaline electrolyzed water containing zinc. More specifically, it relates to a therapeutic agent for dermatitis, which contains zinc and alkaline electrolyzed water as active ingredients.
【０００２】[0002]
【従来の技術】アルカリ電解水は、医療用電解水生成器
なども販売されており、効能として糖尿病、アトピー性
皮膚炎、胃腸内異常発酵、慢性下痢、消化不良、胃酸過
多などが知られている。2. Description of the Related Art Alkaline electrolyzed water is also sold in medical electrolyzed water generators and the like, and its effects such as diabetes, atopic dermatitis, gastrointestinal abnormal fermentation, chronic diarrhea, indigestion, and excessive gastric acid are known. There is.
【０００３】亜鉛はヒトの全ての組織および体液中に含
まれており、鉄に次いで含有量の多い微量金属である。Zinc is a trace metal contained in all human tissues and body fluids, and the second highest content of metal after iron.
【０００４】亜鉛の生理作用としては、成長・骨格の発
育、皮膚及びその付属器官の新陳代謝の活性化、生殖機
能維持、味覚・臭覚の維持、精神・行動への影響、免疫
機能増加などが知られている。[0004] Zinc is known to have physiological functions such as growth and skeletal development, activation of metabolism of skin and its accessory organs, maintenance of reproductive function, maintenance of taste and smell, influence on mental and behavior, increase of immune function and the like. Has been.
【０００５】[0005]
【発明が解決しようとする課題】本発明の目的は、糖尿
病、胃腸内異常発酵、慢性下痢、消化不良、胃酸過多や
アトピー性皮膚炎などの皮膚疾患の諸症状（かゆみ、か
ぶれ、びらん、ただれ、ひび、あかぎれ、湿疹、潰瘍、
湿潤等）などに対して有効なアルカリ性電解水の効力を
更に高めた治療用組成物を提供することである。DISCLOSURE OF THE INVENTION The object of the present invention is to provide various symptoms of skin diseases such as diabetes, abnormal gastrointestinal fermentation, chronic diarrhea, indigestion, gastric hyperacidity and atopic dermatitis (itch, rash, erosion, soreness). , Cracks, cracks, eczema, ulcers,
It is intended to provide a therapeutic composition in which the efficacy of alkaline electrolyzed water which is effective against (wetting, etc.) is further enhanced.
【０００６】[0006]
【課題を解決するための手段】本発明者は、イオン電解
水の種々の効能を検討している途上、亜鉛がイオン電解
水の消炎作用を増強することを見いだし、更にその知見
に基づき本発明を完成した。すなわち、本発明は亜鉛を
含有することを特徴とするアルカリ性電解水である。特
に亜鉛およびアルカリ性電解水を有効成分として含有す
る組成物はアトピー性皮膚炎の治療剤として有用であ
る。Means for Solving the Problems The present inventors have found that zinc enhances the anti-inflammatory action of ionic electrolyzed water while studying various effects of ionic electrolyzed water, and based on this finding, the present invention Was completed. That is, the present invention is alkaline electrolyzed water containing zinc. In particular, a composition containing zinc and alkaline electrolyzed water as active ingredients is useful as a therapeutic agent for atopic dermatitis.
【０００７】本発明のイオン電解水は市販の生成器など
を用いて製造することができる。用いる亜鉛としては、
化合物として有機物および無機物を含むものすべてをい
い、例えば硫酸亜鉛、グルコン酸亜鉛などの内服に適し
た亜鉛化合物を使用することができる。The ionic electrolyzed water of the present invention can be produced using a commercially available generator or the like. The zinc used is
The compounds include all those containing organic substances and inorganic substances, and for example, zinc compounds suitable for internal administration such as zinc sulfate and zinc gluconate can be used.
【０００８】本発明において、亜鉛イオンの有効配合濃
度は、１０〜２００ｐｐｍであり、好ましくは１０〜１
００ｐｐｍである。In the present invention, the effective compounding concentration of zinc ion is 10 to 200 ppm, preferably 10 to 1
00 ppm.
【０００９】本発明の組成物は、成人男子に一日２００
ｍｌ〜３０００ｍｌを投与すればよく、好ましくは２０
０ｍｌ〜５００ｍｌである。The composition of the present invention is applied to an adult male at a daily dose of 200
It is sufficient to administer ml to 3000 ml, preferably 20
It is 0 ml to 500 ml.
【００１０】本発明の組成物は、そのまま治療用飲料水
としてあるいは必要に応じて他の公知の添加剤、例え
ば、着色剤、矯味矯臭剤、界面活性剤などを混合して常
法により、内服液剤、ドリンク剤などにすることができ
る。The composition of the present invention is used as a therapeutic drinking water as it is, or if necessary, other known additives such as a colorant, a flavoring agent and a surfactant are mixed, and the composition is orally administered by a conventional method. It can be a liquid preparation, a drink preparation, or the like.
【００１１】着色剤としては、例えばタール色素、酸化
チタン等が挙げられる。Examples of colorants include tar dyes and titanium oxide.
【００１２】矯味矯臭剤としては、例えばクエン酸、ア
ジピン酸、アスコルビン酸、メントール等が挙げられ
る。Examples of the corrigent include citric acid, adipic acid, ascorbic acid, menthol and the like.
【００１３】界面活性剤としては、例えばポリオキシエ
チレン硬化ヒマシ油、モノステアリン酸ソルビタン、モ
ノパルミチン酸ソルビタン、モノラウリン酸ソルビタ
ン、ポリオキシエチレンポリオキシプロピレンブロック
コポリマー、ポリソルベート類、ラウリル硫酸ナトリウ
ム、マクロゴール類、ショ糖脂肪酸エステル、レシチ
ン、エタノールなどが挙げられる。Examples of the surfactant include polyoxyethylene hydrogenated castor oil, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, polyoxyethylene polyoxypropylene block copolymers, polysorbates, sodium lauryl sulfate and macrogols. , Sucrose fatty acid ester, lecithin, ethanol and the like.
【００１４】内服液剤、ドリンク剤の場合、必要に応じ
て他の生理活性成分、ミネラル、ビタミン、アミノ酸、
臓器抽出物、ホルモン、栄養成分、香料等を混合するこ
とにより、嗜好性をもたせることもできる。In the case of oral liquids and drinks, other physiologically active ingredients, minerals, vitamins, amino acids, if necessary,
It is also possible to impart a palatability by mixing an organ extract, a hormone, a nutritional component, a fragrance and the like.
【００１５】これらの医薬品として、許容される添加物
はいずれも、一般的に製剤に用いられるものが使用でき
る。As these medicinal products, any of the additives generally accepted for use in the preparation can be used.
【００１６】[0016]
【発明の効果】本発明によりイオン電解水の効果が増強
され、糖尿病、胃腸内異常発酵、慢性下痢、消化不良、
胃酸過多やアトピー性皮膚炎などの皮膚疾患の諸症状
（かゆみ、かぶれ、びらん、ただれ、ひび、あかぎれ、
湿疹、潰瘍、湿潤等）などの治療及び発生の予防もでき
る。INDUSTRIAL APPLICABILITY According to the present invention, the effect of electrolyzed water is enhanced, and diabetes, abnormal gastrointestinal abnormal fermentation, chronic diarrhea, indigestion,
Symptoms of skin diseases such as hyperacidity and atopic dermatitis (itch, rash, erosion, sore, cracks, cracks,
Eczema, ulcer, dampness, etc.) can be treated and the occurrence thereof can be prevented.
【００１７】また、血流の増加による冷え症、肩こり、
しもやけなどの治療にも有効である。In addition, coldness due to increased blood flow, stiff shoulders,
It is also effective for treatment of frostbite.
【００１８】特にアトピー性皮膚炎は１型および４型の
アレルギー反応が関与していると考えられるので、それ
ぞれのアレルギー反応を反映するカラゲニンによるfood
padの浮腫、ジニトロフルオロベンゼン（ＤＮＦＢ）に
よる耳介の感作の二つの実験をマウスを用いて行った。
また、活性酸素や局所における炎症を反映する虚血性浮
腫の実験を同じくマウスを用いて行った。Particularly, since atopic dermatitis is considered to be involved in type 1 and type 4 allergic reactions, foods by carrageenin that reflect each type of allergic reaction.
Two experiments of pad edema and sensitization of the auricle with dinitrofluorobenzene (DNFB) were performed using mice.
In addition, an experiment of ischemic edema reflecting active oxygen and local inflammation was also conducted in the same mouse.
【００１９】試験例１（カラゲニン足浮腫試験） （検体） 検体１；カラゲニン（２Ｗ／Ｖ％）＋蒸留水 検体２；カラゲニン（２Ｗ／Ｖ％）＋アルカリ電解水 検体３；カラゲニン（２Ｗ／Ｖ％）＋アルカリ電解水
（硫酸亜鉛を１．５ｍＭ含有） 検体４；カラゲニン（２Ｗ／Ｖ％）＋蒸留水（硫酸亜鉛
を１．５ｍＭ含有） （実験動物）ＩＣＲ系雄性マウス（６Ｗ）を１群４匹用
いた。Test Example 1 (Carrageenin paw edema test) (Sample) Sample 1; Carrageenin (2 W / V%) + distilled water Sample 2; Carrageenin (2 W / V%) + alkaline electrolyzed water Sample 3; Carrageenin (2 W / V) %) + Alkaline electrolyzed water (containing 1.5 mM zinc sulfate) Specimen 4; carrageenin (2 W / V%) + distilled water (containing 1.5 mM zinc sulfate) (experimental animal) 1 male ICR mouse (6 W) A group of 4 animals was used.
【００２０】（実験方法）各群にアルカリ電解水、アル
カリ電解水（硫酸亜鉛を１．５ｍＭ含有）、蒸留水、蒸
留水（硫酸亜鉛を１．５ｍＭ含有）を給水瓶にてマウス
が自然に飲用するようにし、７日間与えた後に２０μｌ
のカラゲニン（２Ｗ／Ｖ％）を足蹠に注射し、注射後の
足蹠の浮腫を時間を追って測定した。(Experimental Method) Alkaline electrolyzed water, alkaline electrolyzed water (containing 1.5 mM of zinc sulfate), distilled water, and distilled water (containing 1.5 mM of zinc sulfate) were added to each group in a water bottle to allow mice to spontaneously move. 20 μl after drinking for 7 days
Carrageenan (2 W / V%) was injected into the footpad, and the edema of the footpad after the injection was measured over time.
【００２１】その他は「生物系科学実験講座１２、炎症
とアレルギー、第１８頁〜第２９頁（広川書店）」に従
って行った。Others were performed according to "Biological Science Experiment Course 12, Inflammation and Allergy, pp. 18-29 (Hirokawa Shoten)".
【００２２】（結果） 実験結果は表１および図
１に示す。(Results) The experimental results are shown in Table 1 and FIG.
【００２３】[0023]
【表１】 [Table 1]
【００２４】試験例２（ＤＮＦＢによる耳介の感作試
験） 検体５；ＤＮＦＢ＋蒸留水 検体６；ＤＮＦＢ＋蒸留水（硫酸亜鉛を４４０ｐｐｍ、
亜鉛として１００ｐｐｍを含む） 検体７；ＤＮＦＢ＋アルカリ電解水 検体８；ＤＮＦＢ＋アルカリ電解水（硫酸亜鉛を４４０
ｐｐｍ、亜鉛として１００ｐｐｍを含む） （実験動物）Ｂａｌｂ／ｃマウス（雌性、６週令）を各
群１０匹用いた。Test Example 2 (Auricle Sensitization Test with DNFB) Sample 5; DNFB + distilled water Sample 6; DNFB + distilled water (440 ppm zinc sulfate,
Specimen 7; DNFB + alkaline electrolyzed water Specimen 8; DNFB + alkaline electrolyzed water (zinc sulfate 440
ppm, including 100 ppm as zinc) (Experimental animal) Balb / c mice (female, 6 weeks old) were used in each group of 10 mice.
【００２５】（実験方法）マウス各群に、各検体を給水
瓶にてマウスが自然に飲用するようにし、１４日間与え
た。その後剃毛したマウスの背部に２５μｌの０．５％
ＤＮＦＢを２日連続して塗布し、マウスを感作した。さ
らに５日後に１０μｌの０．２％ＤＮＦＢを右耳介に塗
布した。その後右耳介は腫脹するが、左右の耳介の厚さ
の差を２４、４８、７２時間後に測定した。詳しくはIc
hiro Katayama, Nishioka Kiyoshi,Int.Archs.Allergy
appl.Immun.,第７６巻、第１０１頁〜第１０６頁（１９
８５年）に従って行った。(Experimental method) Each sample was given to each group of mice in a water bottle so that the mice could naturally drink it for 14 days. Then 25 μl of 0.5% on the back of the shaved mouse
The mouse was sensitized by applying DNFB for 2 consecutive days. After 5 days, 10 μl of 0.2% DNFB was applied to the right auricle. After that, the right auricle swells, but the difference in thickness between the left and right auricles was measured after 24, 48, and 72 hours. For more information Ic
hiro Katayama, Nishioka Kiyoshi, Int.Archs.Allergy
appl.Immun., Vol. 76, pp. 101-106 (19
1985).
【００２６】（結果）実験結果は表２および図２に示
す。(Results) The experimental results are shown in Table 2 and FIG.
【００２７】[0027]
【表２】 [Table 2]
【００２８】試験例３（虚血性足浮腫試験） （検体群） 検体９；輪ゴム＋蒸留水 検体１０；輪ゴム＋アルカリ電解水 検体１１；輪ゴム＋アルカリ電解水（硫酸亜鉛を１．５
ｍＭ含有） 検体１２；輪ゴム＋蒸留水（硫酸亜鉛を１．５ｍＭ含
有） （実験動物）ＩＣＲ系雄性マウス（６Ｗ）を１群４匹用
いた。Test Example 3 (Ischemic paw edema test) (Sample group) Sample 9; Rubber band + distilled water Sample 10; Rubber band + alkaline electrolyzed water Sample 11; Rubber band + alkaline electrolyzed water (1.5% zinc sulfate)
mM contained) Specimen 12; rubber band + distilled water (containing 1.5 mM zinc sulfate) (experimental animal) ICR male mice (6 W) were used in groups of 4 mice.
【００２９】（実験方法）マウス各群にアルカリ電解
水、アルカリ電解水（硫酸亜鉛を１．５ｍＭ含有）、蒸
留水、蒸留水（硫酸亜鉛を１．５ｍＭ含有）を給水瓶に
てマウスが自然に飲用するようにし、７日間与えた。(Experimental method) Alkaline electrolyzed water, alkaline electrolyzed water (containing 1.5 mM of zinc sulfate), distilled water, and distilled water (containing 1.5 mM of zinc sulfate) were added to each group of mice in a water bottle to allow the mice to naturally And was given for 7 days.
【００３０】その他は大柳善彦著「Ｂｉｏｓｃｉｅｎｃ
ｅ Ｓｅｒｉｅｓ」第９６頁〜第１００頁（化学同人
社）に従って行った。Others are written by Yoshihiko Oyanagi, "Bioscience."
e Series ", pages 96 to 100 (Kagaku Dojinsha Co., Ltd.).
【００３１】（結果） 実験結果は表３および図
３に示す。(Results) The experimental results are shown in Table 3 and FIG.
【００３２】[0032]
【表３】 [Table 3]
【００３３】[0033]
【実施例】以下実施例を挙げ、本発明を具体的に説明す
る。EXAMPLES The present invention will be specifically described with reference to the following examples.
【００３４】実施例１ 市販の医療用電解水生成器を用いて生成したアルカリ電
解水５００ｍｌに硫酸亜鉛を１５０ｍｇ含有させ治療用
飲料水とした。Example 1 150 mg of zinc sulfate was added to 500 ml of alkaline electrolyzed water produced using a commercially available electrolyzed water generator for medical use to prepare drinking water for treatment.
【００３５】実施例２ 市販の医療用電解水生成器を用いて生成したアルカリ電
解水４００ｍｌにグルコン酸亜鉛を２８０ｍｇ含有させ
治療用飲料水とした。EXAMPLE 2 280 mg of zinc gluconate was added to 400 ml of alkaline electrolyzed water produced by using a commercially available electrolyzed water generator for medical use to prepare drinking water for treatment.
【００３６】実施例３ （処方例） 硫酸亜鉛 ３０ｍｇ ビタミンＢ2リン酸エステル ２３ｍｇ ビオチン ８００ｍｇ 上記薬剤と、砂糖およびソルビットを１５ｇ、安息香酸
ナトリウム３０ｍｇ、クエン酸ナトリウム３５０ｍｇ、
クエン酸５ｍｇ、着香料微量に市販の医療用電解水生成
器を用いて生成したアルカリ電解水に混合溶解し２００
ｍｌの内服液剤とした。Example 3 (Formulation example) Zinc sulfate 30 mg Vitamin B2 phosphate 23 mg Biotin 800 mg Sugar and sorbitol 15 g, sodium benzoate 30 mg, sodium citrate 350 mg
5 mg of citric acid and a small amount of flavoring agent were mixed and dissolved in alkaline electrolyzed water produced using a commercially available electrolyzed water generator for medical use, and 200
It was used as an oral liquid preparation of ml.
【図１】縦軸に、増加した足蹠の厚さ（ｍｍ）、横軸に
カラゲニン注射後の時間（ｈｒ）を示した相関図であ
る。FIG. 1 is a correlation diagram showing the increased footpad thickness (mm) on the vertical axis and the time (hr) after carrageenin injection on the horizontal axis.
【図２】縦軸に、左右の耳介の厚さの差（ｍｍ）、横軸
に右耳介にＤＮＦＢを塗布した後の時間を示した相関図
である。FIG. 2 is a correlation diagram in which the vertical axis represents the difference (mm) in thickness between the left and right auricles, and the horizontal axis represents the time after applying DNFB to the right auricle.
【図３】縦軸に、増加した足蹠の厚さ（ｍｍ）、横軸に
各検体を示した相関図である。FIG. 3 is a correlation diagram showing the increased footpad thickness (mm) on the vertical axis and each sample on the horizontal axis.
Claims (2)
性電解水。1. Alkaline electrolyzed water containing zinc.
して含有することを特徴とする皮膚炎治療剤。2. A therapeutic agent for dermatitis, which contains zinc and alkaline electrolyzed water as active ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7175968A JPH0925236A (en) | 1995-07-12 | 1995-07-12 | Alkaline electrolytic water containing zinc |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7175968A JPH0925236A (en) | 1995-07-12 | 1995-07-12 | Alkaline electrolytic water containing zinc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0925236A true JPH0925236A (en) | 1997-01-28 |
Family
ID=16005405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7175968A Pending JPH0925236A (en) | 1995-07-12 | 1995-07-12 | Alkaline electrolytic water containing zinc |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0925236A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009526083A (en) * | 2006-02-10 | 2009-07-16 | イーエルシー マネージメント エルエルシー | Inorganic ions in structured water |
| US8834445B2 (en) | 2006-01-20 | 2014-09-16 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing peritonitis with oxidative reductive potential water solution |
| US8840873B2 (en) | 2005-03-23 | 2014-09-23 | Oculus Innovative Sciences, Inc. | Method of treating second and third degree burns using oxidative reductive potential water solution |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| US9498548B2 (en) | 2005-05-02 | 2016-11-22 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
| JP2018131469A (en) * | 2010-07-22 | 2018-08-23 | リベン ファーマシューティカルズ インコーポレイテッド | Methods of treating or ameliorating diseases and enhancing performance comprising use of magnetic dipole stabilized solution |
| US10342825B2 (en) | 2009-06-15 | 2019-07-09 | Sonoma Pharmaceuticals, Inc. | Solution containing hypochlorous acid and methods of using same |
-
1995
- 1995-07-12 JP JP7175968A patent/JPH0925236A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| US9642876B2 (en) | 2003-12-30 | 2017-05-09 | Sonoma Pharmaceuticals, Inc. | Method of preventing or treating sinusitis with oxidative reductive potential water solution |
| US10016455B2 (en) | 2003-12-30 | 2018-07-10 | Sonoma Pharmaceuticals, Inc. | Method of preventing or treating influenza with oxidative reductive potential water solution |
| US8840873B2 (en) | 2005-03-23 | 2014-09-23 | Oculus Innovative Sciences, Inc. | Method of treating second and third degree burns using oxidative reductive potential water solution |
| US9498548B2 (en) | 2005-05-02 | 2016-11-22 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
| US8834445B2 (en) | 2006-01-20 | 2014-09-16 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing peritonitis with oxidative reductive potential water solution |
| US9072726B2 (en) | 2006-01-20 | 2015-07-07 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| US9782434B2 (en) | 2006-01-20 | 2017-10-10 | Sonoma Pharmaceuticals, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| JP2009526083A (en) * | 2006-02-10 | 2009-07-16 | イーエルシー マネージメント エルエルシー | Inorganic ions in structured water |
| US10342825B2 (en) | 2009-06-15 | 2019-07-09 | Sonoma Pharmaceuticals, Inc. | Solution containing hypochlorous acid and methods of using same |
| JP2018131469A (en) * | 2010-07-22 | 2018-08-23 | リベン ファーマシューティカルズ インコーポレイテッド | Methods of treating or ameliorating diseases and enhancing performance comprising use of magnetic dipole stabilized solution |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bassett et al. | A comparative study of tea‐tree oil versus benzoylperoxide in the treatment of acne | |
| JP2009242413A (en) | Medicine based on amino acid | |
| JPH021127B2 (en) | ||
| JPH08325156A (en) | Skin preparation for external use, drink and food product containing steviol glycoside | |
| WO2004039315A2 (en) | Method for treating wounds to promote healing | |
| JPH0925236A (en) | Alkaline electrolytic water containing zinc | |
| JPH0647535B2 (en) | Anti-inflammatory composition | |
| Williams et al. | Further studies of the absorption, distribution, and elimination of thiouracil | |
| JP2000186028A (en) | Cosmetic | |
| JPH06199688A (en) | Remedy composition for comedo | |
| JP3182564B2 (en) | Nutrition composition | |
| US3928578A (en) | Composition for control of white muscle disease | |
| BG100687A (en) | Use of dimeticone for treating aphthae and stomatitis | |
| JP2004229534A (en) | Hydrolyzed eggshell membrane-containing drink | |
| CN109069532A (en) | Composition containing chromium is for improving health and body-building | |
| JPH06199695A (en) | Agent for amelioration and treatment of diabetes | |
| CN107530367A (en) | Oral care composition | |
| US7262170B2 (en) | Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
| JP4009682B2 (en) | Adrenaline and noradrenaline secretion promoting composition | |
| JPS6239512A (en) | Cosmetic containing carpronium chloride | |
| FR2485371A1 (en) | NOVEL COMPOSITION FOR THERAPEUTIC USE BASED ON LYSINE AND ARGININE | |
| EP0073173A1 (en) | Products extracted from invertebrate sea-animals, their preparation and their uses in dietetics,pharmaceutics and cosmetology | |
| Vines | The parathyroid glands in relation to disease | |
| Joelsson | Shark liver oil: Nature's amazing healer | |
| JPH10114650A (en) | Improver for aqueous body fluid and composition for oral administration comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060517 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061003 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070214 |